Welcome to our dedicated page for Vanda Pharma news (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharma stock.
Vanda Pharmaceuticals Inc. (VNDA) is a biopharmaceutical innovator developing therapies for complex medical conditions with limited treatment options. This news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time information about VNDA's sleep-wake disorder treatments, psychiatric therapies, and neurology pipeline. Our curated collection includes FDA decision updates, clinical trial results, financial earnings reports, and partnership announcements – all critical for understanding the company's market position.
Bookmark this page for streamlined tracking of Vanda's progress in antisense oligonucleotide research and commercialization efforts. Regular updates ensure you stay informed about HETLIOZ developments, Fanapt market performance, and emerging therapies in the company's clinical pipeline.
Vanda Pharmaceuticals (VNDA) announced its participation in the Jefferies 2022 Global Healthcare Conference set for June 9, 2022, at 3:30 p.m. ET in New York City. The corporate presentation will be available live on Vanda's website. Investors are encouraged to join early to ensure proper access. An archived version of the conference will be accessible on the website for approximately 30 days post-event. Vanda focuses on developing innovative therapies to meet significant medical needs and improve patient lives.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced its participation in the SLEEP 2022 conference in Charlotte, North Carolina, from June 4-8, 2022. On June 7, scientific presentations will focus on topics such as genetic aberrations linked to sleep disturbances and observational studies on sleep-wake phase disorders. Key presentations by Dr. Sandra Paulina Smieszek will include a novel missense variant in Melanopsin associated with delayed sleep. Vanda aims to develop innovative therapies for unmet medical needs.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced its participation at Digestive Disease Week (DDW) 2022, taking place from May 21-24 in San Diego, CA. The company will present two significant studies by Dr. Sandra Paulina Smieszek, Head of Genetics. The first presentation on May 21 focuses on macrophage polarization in gastroparesis, while the second on May 23 discusses the gene set enrichment analysis in Ehlers Danlos syndrome patients with gastroparesis. For more details, visit DDW's website.
Vanda Pharmaceuticals (Nasdaq: VNDA) reported a net loss of $6.4 million for Q1 2022, a significant shift from a net income of $8.7 million in Q1 2021. Total net product sales decreased by 4% to $60.2 million, with HETLIOZ® sales down 6% to $37.0 million. The company is optimistic about expanding access to HETLIOZ® for Medicaid patients and completing the Fanapt® bipolar study by year-end. Financial guidance for 2022 is set at $240 to $280 million in total revenues, with a year-end cash expectation exceeding $440 million.
Vanda Pharmaceuticals (VNDA) will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:00 p.m. PT (7:00 p.m. ET) in Las Vegas, Nevada. The presentation will be available live on the company's website, and an archived version will be accessible for approximately 30 days following the event. Vanda focuses on developing innovative therapies to meet high unmet medical needs for patients.
Vanda Pharmaceuticals (Nasdaq: VNDA) will announce its first quarter 2022 financial results on May 5, 2022, after market close. A conference call is scheduled for 4:30 PM ET on the same day to discuss the results and corporate activities. Investors can participate via phone or by accessing a live broadcast on Vanda's website. A replay will be available starting at 7:30 PM ET the same day until May 12, 2022. Vanda is focused on developing innovative therapies for unmet medical needs.
Vanda Pharmaceuticals (VNDA) reported Q4 and full-year 2021 results, showcasing total net product sales of $68.0 million in Q4 and $268.7 million for the year, reflecting increases of 1% and 8%, respectively. HETLIOZ® sales were $44.1 million in Q4, while Fanapt® reached $24.0 million. Net income for Q4 decreased to $7.1 million from $8.2 million in Q4 2020, but annual net income rose to $33.2 million from $23.3 million. Vanda anticipates 2022 revenue guidance of $240 to $280 million. A Phase III study of tradipitant did not meet its primary endpoint, prompting further analysis.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is set to release its fourth quarter and full year 2021 financial results on February 23, 2022, after market close. A conference call will occur at 4:30 PM ET on the same day, where management will discuss the results and corporate activities. Investors can participate by calling 1-866-688-9426 (domestic) or 1-409-216-0816 (international) using passcode 5373895. A replay of the call will be available from 7:30 PM ET the same day until March 2, 2022.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced disappointing results from the Phase III study of tradipitant for treating gastroparesis, as it failed to meet its primary endpoint on nausea reduction. However, exploratory analyses suggest that the drug may have significant benefits when accounting for certain patient factors. Tradipitant demonstrated a similar safety profile to placebo, with diarrhea as the most common side effect. Vanda plans further data analysis and intends to pursue regulatory submissions, emphasizing their commitment to addressing unmet medical needs in gastroparesis.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced a License Agreement with MSN Pharmaceuticals and Impax Laboratories to resolve patent litigation over the generic version of its drug HETLIOZ (tasimelteon). The agreement allows MSN and Impax to market their version of HETLIOZ in the U.S. starting March 13, 2035, or July 27, 2035, if Vanda obtains pediatric exclusivity. The settlement includes a release of all claims from the litigation and is pending review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
